Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer

• Published in: BMC cancer Vol. 4; no. 1; p. 36
• Main Authors: Kuehr, Thomas, Ruff, Paul, Rapoport, Bernardo L, Falk, Stephen, Daniel, Francis, Jacobs, Conrad, Davidson, Neville, Thaler, Josef, Boussard, Blandine, Carmichael, James
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.07.2004; BioMed Central; BMC
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Diarrhea - chemically induced; Fatigue - chemically induced; Female; Fluorouracil - administration & dosage; Hematologic Diseases - chemically induced; Humans; Irinotecan; Leucovorin - administration & dosage; Male; Maximum Tolerated Dose; Middle Aged; Nausea - chemically induced; Shock, Septic - chemically induced; Stomatitis - chemically induced; Survival Rate

This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal ca...